title: Estimated number of children with cancer eligible for hyperthermia based on population- and treatment-related criteria.
abstract: Patients with recurrent, progressed or otherwise, therapy resistant malignancies, whose diseases are not amenable to standard therapies, may benefit from hyperthermia (HT). Based on the number of 1600 newly diagnosed malignancies, in patients < 15 years of age, per annum of which 70% are successfully treated on the standard treatment protocols of the German Society of Pediatric Oncology and Hematology (GPOH) and allowing for various drop-outs for reasons such as lack of established protocols, insufficient state of health and others, this means that as many as 100 children per annum can be expected to be enrolled into phase I/II trials in Germany. In view of the promising results in adults, phase I/II HT studies have also been performed in children and adolescents with recurrent or advanced malignancies including Ewing's tumours, aggressive fibromatosis, and germ cell tumours. Recent results in paediatric studies indicate the feasibility of both regional deep HT and whole body HT, and the best case analysis reveals promising response rates (CR + PR) as well as some long-term remissions. Technical modifications, due to the smaller body diameters, led to mean intratumoural temperatures in paediatric patients similar to those reported for adults in whom an improved outcome was demonstrated. The results in children and adolescents even suggest that introduction of HT into standard treatment protocols may be promising to improve tumour response and event-free survival in patients with poor risk malignancies of childhood.
authors.affiliation: Department of Pediatric Hematology and Oncology, Heinrich-Heine University, Düsseldorf, Germany. wessalowski@med.uni-duesseldorf.de
authors.forename: R
authors.initials: R
authors.lastname: Wessalowski
authors.forename: R
authors.initials: R
authors.lastname: Van Heek-Romanowski
authors.forename: R D
authors.initials: RD
authors.lastname: Issels
authors.forename: H T
authors.initials: HT
authors.lastname: Jürgens
authors.forename: U
authors.initials: U
authors.lastname: Göbel
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D006979:Hyperthermia, Induced; D009369:Neoplasms / Q000145:classification / Q000188:drug therapy / Q000628:therapy*; D018579:Patient Selection; D012042:Registries